{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:18:05Z","timestamp":1793765885533,"version":"4.6.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40264-020-01036-w","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T03:04:54Z","timestamp":1612235094000},"page":"515-530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Upadacitinib in Rheumatoid Arthritis: A Benefit\u2013Risk Assessment Across a Phase III Program"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3478-5665","authenticated-orcid":false,"given":"Philip G.","family":"Conaghan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Da Silva-Tillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Enejosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9226-979X","authenticated-orcid":false,"given":"Stanley","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1382-7299","authenticated-orcid":false,"given":"William","family":"Rigby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"1036_CR1","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"key":"1036_CR2","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389:2328\u201337.","journal-title":"Lancet"},{"key":"1036_CR3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.semarthrit.2006.08.006","volume":"36","author":"Y Alamanos","year":"2006","unstructured":"Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"1036_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/14397595.2013.854059","volume":"24","author":"H Yamanaka","year":"2013","unstructured":"Yamanaka H, Sugiyama N, Inoue E, et al. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol. 2013;24:33\u201340.","journal-title":"Mod Rheumatol."},{"key":"1036_CR5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/1756-185X.12695","volume":"18","author":"I Sengul","year":"2015","unstructured":"Sengul I, Akcay-Yalbuzdag S, Ince B, et al. Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis. Int J Rheum Dis. 2015;18:640\u20135.","journal-title":"Int J Rheum Dis."},{"key":"1036_CR6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1\u201325.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1036_CR8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","volume":"158","author":"W Wang","year":"2018","unstructured":"Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502\u201316.","journal-title":"Eur J Med Chem."},{"key":"1036_CR9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/OARRR.S131668","volume":"9","author":"AE Bello","year":"2017","unstructured":"Bello AE, Perkins EL, Jay R, et al. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol. 2017;9:67\u201379.","journal-title":"Open Access Rheumatol."},{"key":"1036_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3\u201315.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10067-018-4340-7","volume":"38","author":"C Yu","year":"2019","unstructured":"Yu C, Jin S, Wang Y, et al. Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. Clin Rheumatol. 2019;38:727\u201338.","journal-title":"Clin Rheumatol."},{"key":"1036_CR12","first-page":"658","volume":"36","author":"B Combe","year":"2018","unstructured":"Combe B, Lula S, Boone C, et al. Effects of biologic disease-modifying anti-rheumatic drugs on the radiographic progression of rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol. 2018;36:658\u201367.","journal-title":"Clin Exp Rheumatol."},{"key":"1036_CR13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","volume":"73","author":"JL Nam","year":"2014","unstructured":"Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516\u201328.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","volume":"13","author":"JR Kalden","year":"2017","unstructured":"Kalden JR, Schulze-Koops H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat Rev Rheumatol. 2017;13:707\u201318.","journal-title":"Nat Rev Rheumatol."},{"key":"1036_CR15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2666","volume":"11","author":"A Rubbert-Roth","year":"2009","unstructured":"Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11:S1.","journal-title":"Arthritis Res Ther."},{"key":"1036_CR16","unstructured":"EMA. Xeljanz (tofacitinib): Summary of product characteristics 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf. Accessed 1 Dec 2020."},{"key":"1036_CR17","unstructured":"EMA. Olumiant (baricitinib): Summary of product characteristics 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf. Accessed 1 Dec 2020."},{"key":"1036_CR18","unstructured":"EMA. RINVOQ (upadacitinib). Summary of product characteristics. 2019. https:\/\/www.emaeuropaeu\/en\/documents\/product-information\/rinvoq-epar-product-information_enpdf. Accessed 1 Dec 2020."},{"key":"1036_CR19","unstructured":"EMA. Jyseleca (filgotinib): Summary of product characteristics 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf. Accessed 1 Dec 2020."},{"key":"1036_CR20","unstructured":"Gilead. Gilead receives complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis 2020. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/8\/gilead-receives-complete-response-letter-for-filgotinib-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis. Accessed 1 Dec 2020."},{"key":"1036_CR21","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","volume":"389","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389:2338\u201348.","journal-title":"Lancet"},{"key":"1036_CR22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457\u201368.","journal-title":"Lancet"},{"key":"1036_CR23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652\u201362.","journal-title":"N Engl J Med."},{"key":"1036_CR24","unstructured":"A study in moderate to severe rheumatoid arthritis (RA-BEAM). https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01710358?view=results. Accessed 1 Dec 2020."},{"key":"1036_CR25","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788\u2013800.","journal-title":"Arthritis Rheumatol."},{"issue":"S2","key":"1036_CR26","first-page":"77","volume":"78","author":"B Combe","year":"2019","unstructured":"Combe B, Kivitz A, Tanaka Y, et al. LB0001 Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Ann Rheum Dis. 2019;78(S2):77\u20138.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR27","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377\u201386.","journal-title":"N Engl J Med."},{"key":"1036_CR28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69:506\u201317.","journal-title":"Arthritis Rheumatol."},{"key":"1036_CR29","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan A, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-na\u00efve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. Arthritis Rheumatol. 2020;72:1607\u201320.","journal-title":"Arthritis Rheumatol."},{"issue":"S2","key":"1036_CR30","first-page":"259","volume":"78","author":"R Westhovens","year":"2019","unstructured":"Westhovens R, Rigby W, van der Heijde D, et al. LB0003 EFficacy and safety of filgotinib for patients with rheumatoid arthritis na\u00efve to methotrexate therapy: FINCH3 primary outcome results. Ann Rheum Dis. 2019;78(S2):259\u201361.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs. placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial. JAMA. 2019;322:315\u201325.","journal-title":"JAMA"},{"key":"1036_CR32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:234.","journal-title":"Nat Rev Rheumatol."},{"key":"1036_CR33","unstructured":"EMA. EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/xeljanz. Accessed 1 Dec 2020."},{"key":"1036_CR34","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1042\u201355.","journal-title":"Arthritis Rheumatol."},{"key":"1036_CR35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol."},{"key":"1036_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","volume":"30","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30:1\u20139.","journal-title":"Mod Rheumatol"},{"key":"1036_CR37","unstructured":"FDA. RINVOQ (upadacitinib) Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211675s000lbl.pdf2019. Accessed 1 Dec 2020."},{"key":"1036_CR38","first-page":"1011","volume":"79","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan A, et al. Efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (SELECT-CHOICE): a double-blind, rnadomized controlled Phase 3 trial [Abstract]. Ann Rheum Dis. 2020;79:1011.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR39","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","volume":"59","author":"H Kameda","year":"2020","unstructured":"Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study. Rheumatology (Oxford). 2020;59:3303\u201313.","journal-title":"Rheumatology (Oxford)"},{"key":"1036_CR40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines G, et al. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137\u201345.","journal-title":"Arthritis Rheum."},{"key":"1036_CR41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-015-0501-8","volume":"17","author":"AM Orbai","year":"2015","unstructured":"Orbai AM, Bingham CO 3rd. Patient reported outcomes in rheumatoid arthritis clinical trials. Curr Rheumatol Rep. 2015;17:28.","journal-title":"Curr Rheumatol Rep."},{"key":"1036_CR42","first-page":"261","volume":"27","author":"D van der Heijde","year":"2000","unstructured":"van der Heijde D. How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol. 2000;27:261\u20133.","journal-title":"J Rheumatol."},{"key":"1036_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020.\u00a0https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2020-eular.2396","volume":"79","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, van Vollenhoven R, Curtis JR, et al. Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis [THU0197]. Ann Rheum Dis. 2020;79:315.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/annrheumdis-2020-eular.1524","volume":"79","author":"K Winthrop","year":"2020","unstructured":"Winthrop K, Nash P, Yamaoka K, et al. Incidence and risk factors for herpes zoster in rheumatoid arthritis patients receiving upadacitinib [THU0218]. Ann Rheum Dis. 2020;79:331.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR46","first-page":"650","volume":"79","author":"K Winthrop","year":"2020","unstructured":"Winthrop K, Calabrese LH, Van den Bosch F, et al. Characterization of serious infections with upadacitinib in patients with rheumatoid arthritis [FRI0141]. Ann Rheum Dis. 2020;79:650.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/annrheumdis-2020-eular.3668","volume":"79","author":"E Choy","year":"2020","unstructured":"Choy E, McInnes I, Cush J, et al. Incidence and risk of venous thromboembolic events among patients with rheumatoid arthritis enrolled in the upadacitinib SELECT clinical trial program [THU0195]. Ann Rheum Dis. 2020;79:313.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR48","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503\u201312.","journal-title":"Lancet"},{"key":"1036_CR49","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513\u201324.","journal-title":"Lancet"},{"key":"1036_CR50","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/annrheumdis-2018-214154","volume":"78","author":"G Burmester","year":"2019","unstructured":"Burmester G, van den Bosch F, Bassette L, et al. Long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis and an inadequate response to csDMARDs: results at 60 weeks from the SELECT-NEXT study. Ann Rheum Dis. 2019;78:735\u20136.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR51","first-page":"360","volume":"78","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Combe B, Hall S, et al. Upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological DMARDs: results at 60 weeks from the SELECT-BEYOND study. Ann Rheum Dis. 2019;78:360\u20131.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR52","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","volume":"78","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78:1454\u201362.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR53","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u201311.","journal-title":"Lancet"},{"key":"1036_CR54","doi-asserted-by":"crossref","unstructured":"Smolen J, Emery P, Rigby W, et al. Upadacitinib as monotherapy in patients with rheumatoid arthritis: results at 48 weeks [abstract]. Arthritis Rheumatol. 2019;71(suppl 10).","DOI":"10.1136\/annrheumdis-2019-eular.491"},{"key":"1036_CR55","first-page":"376","volume":"78","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R, Takeuchi T, Pangan A, et al. Monotherapy with upadacitinib in MTX-naive patients with rheumatod arthritis: results at 48 weeks from the SELECT-EARLY study. Ann Rheum Dis. 2019;78:376\u20137.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR56","unstructured":"FDA. Tofacitinib Medical Review. Application Number 203214Orig1s000 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000MedR.pdf. Accessed 1 Dec 2020."},{"key":"1036_CR57","unstructured":"FDA. Tocilizumab Medical Review. Application Number 125276. 2009. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/125276s000MedR.pdf. Accessed 1 Dec 2020."},{"key":"1036_CR58","unstructured":"FDA. Sarilumab Medical Review. Application Number 761037Orig1s000 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761037Orig1s000MedR.pdf. Accessed 1 Dec 2020."},{"key":"1036_CR59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/14397595.2017.1307899","volume":"28","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Ishii T, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: a 52-week, randomized, single-blind, extension study. Mod Rheumatol. 2018;28:20\u20139.","journal-title":"Mod Rheumatol."},{"key":"1036_CR60","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675\u201384.","journal-title":"Arthritis Rheumatol."},{"key":"1036_CR61","unstructured":"Harigai M, Imafuku S, Sasaki N, et al. Incidence and risk factors for herpes zoster (HZ) in Japanese and global rheumatoid arthritis (RA) populations receiving upadacitinib (UPA). In: The 64th Annual Meeting of the Japanese Society of Rheumatology, 2020."},{"key":"1036_CR62","unstructured":"Yamaoka K, Tanaka Y, Kameda H, et al. Safety profile of upadacitinib (UPA) in Japanese patients (pts) with rheumatoid arthritis (RA). In: The 64th Annual Meeting of the Japanese Society of Rheumatology, 2020;20(Suppl)."},{"key":"1036_CR63","unstructured":"FDA. Baricitinib, a JAK inhibitor for RA. Briefing Information for the April 23, 2018 Meeting of the Arthritis Advisory Committee (AAC). https:\/\/www.fda.gov\/media\/112372\/download. Accessed 1 Dec 2020."},{"key":"1036_CR64","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","volume":"17","author":"TA Simon","year":"2015","unstructured":"Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.","journal-title":"Arthritis Res Ther."},{"key":"1036_CR65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480\u20139.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR66","unstructured":"Choy E, McInnes I, Cush J, et al. MACE and VTE across multiple upadacitinib studies in rheumatoid arthritis: integrated analysis from the SELECT phase 3 clinical program [abstract]. Arthritis Rheumatol. 2019;71(suppl 10)."},{"key":"1036_CR67","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.22039","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Schneeweiss S, Liu J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65:1600\u20137.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1036_CR68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000068427","volume":"70","author":"C Kroegel","year":"2003","unstructured":"Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration. 2003;70:7\u201330.","journal-title":"Respiration."},{"issue":"S2","key":"1036_CR69","first-page":"734","volume":"78","author":"K Queeney","year":"2019","unstructured":"Queeney K, Housley W, Sokolov J, et al. FRI0131 Elucidating the mechanism underlying creatine phosphokinase upregulation with upadacitinib. Ann Reum Dis. 2019;78(S2):734\u20135.","journal-title":"Ann Reum Dis."},{"key":"1036_CR70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2020","unstructured":"Nash P, Kerschbaumer A, D\u00f6rner T, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2020;80:71\u201387.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR71","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","volume":"59","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Kl\u00fcnder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59:531\u201344.","journal-title":"Clin Pharmacokinet."},{"key":"1036_CR72","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-019-00739-3","volume":"58","author":"B Kl\u00fcnder","year":"2019","unstructured":"Kl\u00fcnder B, Mittapalli RK, Mohamed MF, et al. Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I-III cinical trials. Clin Pharmacokinet. 2019;58:1045\u201358.","journal-title":"Clin Pharmacokinet."},{"key":"1036_CR73","doi-asserted-by":"crossref","first-page":"2020-7-5","DOI":"10.7573\/dic.2020-7-5","volume":"9","author":"K Pavelka","year":"2020","unstructured":"Pavelka K, Szekanecz Z, Damjanov N, et al. Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. Drugs Context. 2020;9:2020-7-5.","journal-title":"Drugs Context."},{"key":"1036_CR74","doi-asserted-by":"crossref","unstructured":"Takeuchi T, Rischmueller M, Blanco R, et al. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-na\u00efve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. Mod Rheumatol. 2020:1\u201322.","DOI":"10.1080\/14397595.2020.1847776"},{"issue":"S1","key":"1036_CR75","first-page":"1020","volume":"79","author":"X Zeng","year":"2020","unstructured":"Zeng X, Zhao D, Radominski S, et al. SAT0160 Efficacy and safety of upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis who have had inadequate response to conventional synthetic disease-modifying antirheumatic drugs. Ann Rheum Dis. 2020;79(S1):1020\u20131.","journal-title":"Ann Rheum Dis."},{"key":"1036_CR76","unstructured":"A study to compare upadacitinib (ABT-494) monotherapy to methotrexate (MTX) monotherapy in adults with rheumatoid arthritis (RA) who have not previously taken methotrexate (SELECT-EARLY) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02706873. Accessed 1 Dec 2020."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-01036-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T23:25:29Z","timestamp":1697757929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-01036-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1036"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-01036-w","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"16 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AbbVie Inc. funded this study and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Philip G. Conaghan has received consultancy or speakers\u2019 bureau fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Flexion Therapeutics, Galapagos, Gilead, Janssen, Novartis, and Pfizer. Eduardo Mysler has received research grants and\/or consulting fees from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Pfizer, Roche, and Sandoz. Yoshiya Tanaka has received speaking fees and\/or honoraria from AbbVie GK, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan KK, Janssen Pharmaceutical KK, Mitsubishi-Tanabe Pharma, Novartis, Pfizer Japan Inc., Takeda, Teijin, and YL Biologics and research grants from Asahi-Kasei Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Mitsubishi-Tanabe Pharma, Ono Pharmaceutical, Sanofi KK, Takeda, and UCB Japan. Barbara Da Silva-Tillmann, Tim Shaw, John Liu, Ryan Ferguson, and Jeffrey V. Enejosa are employees of AbbVie and may own AbbVie stock or options. Stanley Cohen has received grant money\/research support from, and has acted as consultant to, Amgen, AbbVie, Boehringer Ingelheim, Pfizer, and Sandoz. Peter Nash has received funding for clinical trials, research grants, and honoraria for lectures and advice from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche, Sandoz, Sanofi-Aventis, and UCB. William Rigby has received grant\/research support from, and has acted as a consultant for, AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer, Roche, and Sun Pharma. Gerd Burmester has acted as consultant and participated in speakers\u2019 bureaus for AbbVie, Eli Lilly, Gilead, and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Studies were conducted in compliance with the Declaration of Helsinki, International Conference on Harmonisation of Technical Regulations for Pharmaceuticals for Human Use guidelines, and applicable local country regulations. All study-related documents were approved by independent ethics committees and institutional review boards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent to participate in the trials.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), provided the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing agreement. Data requests can be submitted at any time, and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study concept\/design, data acquisition, analysis, and interpretation, as well as writing and critical review of the manuscript. All authors provided final approval of the submitted version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}